To date, there are twelve FDA-approved ADCs; two of them, T-DM1 and T-DXd, are indicated for HER2+ breast cancer, with the latter also indicated in patients with HER2+ gastric cancer. The gene discussed is ERBB2; the disease is breast carcinoma.